Reneo Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-77.39	-51.96	-39.77	-19.47	-12.44
Depreciation & Amortization	0.53	0.53	0.05	0.04	0.03
Share-Based Compensation	5.11	4.32	3.89	0.39	0.39
Other Operating Activities	8.07	-0.26	-2.15	0.5	-0.5
Operating Cash Flow	-63.68	-47.36	-37.98	-18.54	-12.51
Capital Expenditures	-0.22	-0.35	-0.2	-0.02	-0.01
Change in Investments	10.74	-57.5	-23.18	7.4	-7.23
Investing Cash Flow	10.52	-57.84	-23.38	7.38	-7.24
Share Issuance / Repurchase	60.87	0.47	85.17	0.09	0.03
Other Financing Activities	-	-	47.24	47.19	24.96
Financing Cash Flow	60.87	0.47	132.41	47.27	24.99
Net Cash Flow	7.71	-104.73	71.05	36.11	5.24
Free Cash Flow	-63.9	-47.71	-38.18	-18.56	-12.52
Free Cash Flow Per Share	-2.08	-1.95	-2.10	-9.15	-6.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).